Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Thematic (Sector/Industry)

United states Financials / Thematic (Sector/Industry)

<ul><li>ICER draft update with little change. In a follow-up to Shroom Shmooz: How Valid Are ICER’s Concerns about MAPS’ MDMA-AT Trials? , we highlight the amended ICER report published on May 14, 2024, which incorporates the public comments it received.</li><li>In short, there is no substantive difference between the updated and initial drafts. The skeptical tone of the integrity of the Phase III trial outcomes and conclusion that the current publicly available evidence is insufficient to assess the overall net benefit of MDMA- AT remain.</li><li>The main difference between the two reports is that the revised version contains more discussion on comorbidities commonly associated with PTSD. </li></ul>

ICER draft update with little change. In a follow-up to Shroom Shmooz: How Valid Are ICER’s Concerns about MAPS’ MDMA-AT Trials? , we highlight the amended ICER report published on May 14, 2024, which incorporates the public comments it received.In short, there is no substantive difference between the updated and initial drafts. The skeptical tone of the integrity of the Phase III trial outcomes and conclusion that the current publicly available evidence is insufficient to assess the overall net benefit of MDMA- AT remain.The main difference between the two reports is that the revised version contains more discussion on comorbidities commonly associated with PTSD. 

Shroom Shmooz - Follow-Up to ICER's Evidence Report on the MDMA- AT Trials